SCHEMBL951176

SCHEMBL951176

O=Cc1ccc(-n2cncn2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 1.00
KDM4E B2RXH2 4/20 1.00
SMN1; SMN2 Q16637 3/20 1.00
FBP1 P09467 1/20 0.61
MAPK1 P28482 1/20 0.55
MAPT P10636 2/20 0.52
HSP90AA1 P07900 1/20 0.52
HTT P42858 1/20 0.52
KCNJ1 P48048 1/20 0.52
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
CYP2A6 P11509 1/20 0.47
TRIM24 O15164 1/20 0.42
TRIM33 Q9UPN9 1/20 0.42
NPSR1 Q6W5P4 1/20 0.40
RAB9A P51151 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6876178 0.84 KDM4E (0.72) ALDH1A1KDM4ESMN1; SMN2FBP1MAPK1
SCHEMBL6876185 0.84 KDM4E (0.72) ALDH1A1KDM4ESMN1; SMN2FBP1MAPK1
SCHEMBL14321150 0.82 KDM4E (0.70) ALDH1A1KDM4ESMN1; SMN2FBP1MAPK1
SCHEMBL6869976 0.82 KDM4E (0.70) ALDH1A1KDM4ESMN1; SMN2FBP1MAPK1
SCHEMBL29450010 0.80 ALDH1A1 (0.67) ALDH1A1KDM4ESMN1; SMN2FBP1MAPK1
SCHEMBL2039106 0.80 ALDH1A1 (0.67) ALDH1A1KDM4ESMN1; SMN2FBP1MAPK1
SCHEMBL6875879 0.79 SMN1; SMN2 (0.66) ALDH1A1KDM4ESMN1; SMN2FBP1MAPT
SCHEMBL6702626 0.79 KDM4E (0.66) ALDH1A1KDM4ESMN1; SMN2FBP1MAPK1
SCHEMBL5535834 0.79 SMN1; SMN2 (0.66) ALDH1A1KDM4ESMN1; SMN2FBP1MAPT
SCHEMBL1609843 0.78 KDM4E (0.64) ALDH1A1KDM4ESMN1; SMN2FBP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 366 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119285637-A Tryptanthrin compound, synthesis method and application thereof 陕西中医药大学 2025-01-10 CN claimed
CN-109867683-B Triazolyl benzaldehyde fluorescein hydrazide Schiff base and preparation method thereof 齐鲁工业大学 2021-08-10 CN claimed
CN-109761992-B Triazolyl benzaldehyde rhodamine hydrazine hydrate Schiff base and preparation method thereof 齐鲁工业大学 2021-03-12 CN claimed
CN-109206405-B Triazolyl quinoline copper complex with AIE property and preparation method thereof 阜阳师范学院 2020-10-27 CN claimed
CN-109206405-A Triazolyl quinoline copper complex with AIE property and preparation method thereof 阜阳师范学院 2019-01-15 CN claimed
CN-107056716-A A kind of triazole benzaldehyde-p-phenylenediamine bi-schiff base and preparation method thereof 齐鲁工业大学 2017-08-18 CN claimed
CN-104119286-B A kind of triazole benzaldehyde-p-phenylenediamine bi-schiff base and preparation method thereof 淄博职业学院 2017-06-20 CN claimed
CN-104119286-A Condensed triazole benzaldehyde p-phenylenediamine bis-Schiff base and preparation method thereof UNIV QILU TECHNOLOGY 2014-10-29 CN claimed
CN-119285637-A Tryptanthrin compound, synthesis method and application thereof 陕西中医药大学 2025-01-10 CN disclosed
US-20240287070-A1 FUSED HETEROCYCLIC DERIVATIVES JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) 2024-08-29 US disclosed
US-20240279227-A1 FUSED HETEROCYCLIC DERIVATIVES JANSSEN BIOTECH, INC. 2024-08-22 US disclosed
US-12016852-B2 Pyrrolidine glycosidase inhibitors ASCENEURON SA (CH) 2024-06-25 US disclosed
US-12016852-B2 Pyrrolidine glycosidase inhibitors ASCENEURON SA (CH) 2024-06-25 US disclosed
CN-117881661-A Condensed heterocyclic derivative 杨森科学爱尔兰无限公司 2024-04-12 CN disclosed
US-5703106-A TREATING VARIOUS CARDIOVASCULAR, UROGENITAL, BRAIN DISORDERS JAPAT LTD. (CH) 1997-12-30 US disclosed
WO-1997011960-A1 ANTAGONISTS OF ENDOTHELIN RECEPTORS JAPAT LTD. (CH) 1997-04-03 WO disclosed
EP-0753004-A1 ANTAGONISTS OF ENDOTHELIN RECEPTORS Japat Ltd (CH) 1997-01-15 EP disclosed
WO-1996033170-A1 N-AROYLAMINO ACID AMIDES AS ENDOTHELIN INHIBITORS NOVARITS AG (CH) 1996-10-24 WO disclosed
WO-1996010559-A1 UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-04-11 WO disclosed
WO-1995026360-A1 ANTAGONISTS OF ENDOTHELIN RECEPTORS JAPAT LTD. (CH) 1995-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287070-A1 FUSED HETEROCYCLIC DERIVATIVES HAVCR2, HCCS, GOT2 ALDH1A1 2000/4885KDM4E 3515/4885SMN1; SMN2 3697/4885
US-12016852-B2 Pyrrolidine glycosidase inhibitors PREP, GAA, DNPEP ALDH1A1 1182/4885KDM4E 2209/4885SMN1; SMN2 2473/4885
US-20240279227-A1 FUSED HETEROCYCLIC DERIVATIVES HAVCR2, HCCS, GOT2 ALDH1A1 2000/4885KDM4E 3515/4885SMN1; SMN2 3697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.